A Phase III, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of COMP360 in participants with treatment-resistant depression

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- diagnosis of major depression without psychotic features - if the current major depressive episode is the first episode of depression, the length of the current episode must be at least 3 months and no more than 2 years - have not responded to an adequate dose and duration of two, three, or four different medications to treat the current episode - agree to discontinue all prohibited medications (study staff will review)

Exclusion Criteria:

- any additional major mental health diagnosis - required psychiatric inpatient care in the past 12 months - treatment with electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode - transcranial magnetic stimulation within the past six months - in a psychological therapy program that will not remain stable for the duration of the study

Conditions & Interventions

Interventions:
Drug: Psilocybin
Conditions:
Mental Health & Addiction
Keywords:
TRD, Treatment Resistant Depression

More Information

Description: MM - Study 3 of 6 - Expedited Study
Contact(s): Interventional Psychiatry Lab Study - ipl@umn.edu
Principal Investigator: Ziad Nahas
Phase: PHASE3
IRB Number: STUDY00020807
System ID: 40285